Shoji, Ayako
Kudo, Kennichi
Murashita, Koichi
Nakaji, Shigeyuki
Igarashi, Ataru
Funding for this research was provided by:
Japan Science and Technology Agency (JPMJPF2210, JPMJCE1302)
Article History
Received: 10 August 2023
Accepted: 6 March 2024
First Online: 25 March 2024
Declarations
:
: This study was approved by the Ethics Committee of the University of Tokyo Faculty of Medicine (2023080NI). The CHAP project was approved by the Ethics Committee of Hirosaki University School of Medicine (2013–062, 2014–014, 2014–377-1, 2016–028-1, 2018–012, 2020–046-4, and 2021–166-3) and conducted in accordance with the principles of the Declaration of Helsinki. All participants in the Iwaki Cohort provided written informed consent to Hirosaki University. Informed consent for all residents in Hirosaki City was obtained by allowing them to out-out of the study in an official newsletter of the city. We had no access to information that could identify individual participants during or after data collection.
: Not applicable.
: AS is an employee of Medilead Inc. and a manager of Healthcare Consulting Inc. KK is Executive Vice President of Integrated Clinical Care Informatics, Inc. AI has received grants from Abbott Japan Inc., Abbvie G.K., Becton, Dickinson and Company, Creative-Ceuticals Inc., Eli Lilly Japan K.K., Gilead Sciences K.K., Intuitive Surgical G.K., Milliman Inc., Pfizer Inc., Sanofi Pasteur Inc., and Terumo Corporation, and personal fees from Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., CSL Behring Japan Inc., FUJIFILM Corporation, Sanofi K.K., and Takeda Pharmaceutical Co., Ltd, outside the submitted work. KM and SN have declared no conflicts of interest.